# Revolution Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/revolution-medicines

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.revmed.com
- Total disclosed funding: $227M
- Latest round: Series C (Jun 5, 2019)
- Investors on record: 18

## About

Based in California, US, and founded in 2014 by David L. Pompliano, David Pompliano, Mark A. Goldsmith, and Martin D. Burke, Revolution Medicines, Inc. develops medicine for the treatment of cancer, by translating frontier oncology targets. In July 2019, Revolution Medicines, Inc. raised USD 100 million in a Series C funding led by Boxer Capital, with participation from BVF Partners, Cormorant Capital, Deerfield Management, Fidelity Investments, Vivo Capital, Casdin Capital, Nextech, Schroders Capital, The Column Group, and Third Rock Ventures. In February 2020, Revolution Medicines, Inc. raised USD 238 million in an IPO, selling 14 million shares at USD 17 per share. The company is listed on Nasdaq under the ticker symbol RVMD and employs approximately x 162 employees. Mark A. Goldsmith is the CEO and president of Revolution Medicines, Inc.

Revolution Medicines, Inc. is developing RMC-4630, which is a central node in the RAS signaling pathway, and RMC-4630 for a range of tumor types featuring specific oncogenic mutations. The company is also developing a portfolio of mutant-selective RAS inhibitors that are cell-active inhibitors of the active, GTP-bound form of RAS, or RAS(ON). In addition, the product pipeline of Revolution Medicines includes RMC-5845, a SOS1 selective inhibitor, and RMC-5552, a 4EBP1/mTORC1 selective inhibitor.

Revolution Medicines, Inc. has generated USD 42.983 million in revenue in the fiscal year ended in December 2020.

## Funding rounds

- Series C, Jun 5, 2019, $100M — Schroders Capital, Vivo Capital, The Column Group, Third Rock Ventures, Nextech, Fidelity Investments, Casdin Capital, Deerfield Management, BVF Partners, Boxer Capital, Cormorant Capital
- Series B, Mar 23, 2018, $56M — Schroders Capital, Harvard Management Company, The Column Group, Bessemer Venture Partners, Third Rock Ventures, Nextech, Pilot House Ventures, Casdin Capital, Partners Healthcare Group, LLC, S-Cubed Capital, Ponoi Capital, The Sobrato Organization
- Series A, Dec 20, 2016, $25M — The Column Group
- Series A, Feb 4, 2015, $45M — Third Rock Ventures

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B, Series C
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series C
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series B, Series C
- Harvard Management Company — Series B
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B, Series C
- Pilot House Ventures (https://capitalatlas.ai/funds/pilot-house-ventures) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B, Series C
- Partners Healthcare Group, LLC — Series B
- S-Cubed Capital — Series B
- Ponoi Capital — Series B
- The Sobrato Organization — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series C
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series C
- Cormorant Capital — Series C